REGN vs TMO
REGN: Regeneron develops and commercializes monoclonal antibody and other biologics therapies across immunology, oncology, infectious disease, and other therapeutic areas. TMO: Global leader in life sciences tools, diagnostics, and laboratory services supporting research, diagnostics, and bioproduction across pharma, biotech, and clinical markets.
Side-by-side fundamentals
| Metric | REGN | TMO | Edge |
|---|---|---|---|
| Price as of 2026-07-09 close | $667.95 | $524.71 | |
| Market cap as of 2026-07-10 | $69.9B | $193.1B | |
| P/E as of 2026-07-10 | 15.80 | 28.21 | REGN lower |
| PEG as of 2026-07-10 | 1.01 | 2.89 | REGN lower |
| Net margin as of 2026-07-10 | +29.6% | +15.2% | REGN higher |
| Gross margin as of 2026-07-10 | +85.7% | +40.9% | REGN higher |
| Operating margin as of 2026-07-10 | +24.3% | +17.5% | REGN higher |
| ROE as of 2026-07-10 | +14.3% | +13.2% | REGN higher |
| ROA as of 2026-07-10 | +11.1% | +6.4% | REGN higher |
| Debt / equity as of 2026-07-10 | 0.09 | 0.83 | REGN lower |
| Revenue growth (YoY) as of 2026-07-10 | +5.9% | +5.4% | REGN higher |
| Revenue CAGR (3y) SEC XBRL | +5.6% | -0.3% | REGN higher |
| Dividend yield as of 2026-07-10 | +0.6% | +0.4% | REGN higher |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-10 | 0.21 | 0.86 | |
| 1-year return as of 2026-07-09 close | +20.9% | +25.0% | TMO higher |
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.